stockrowGlass House Brands Inc.
GLAS Healthcare Drug Manufacturers Specialty & Generic
Glass House Brands Inc.’s revenue for fiscal 2025 (year ended December 2025) was $182.0 million, down 9.41% from fiscal 2024.
- Revenue
- −1.24%
- EPS
- −320.0%
- Free cash flow
- −123.4%
- Total debt
- −17.2%
Quarter to June 2026, against a year earlier
Follow GLAS
Alert me
Glass House Brands Inc. (GLAS) Beneish M-score
Glass House Brands Inc.'s Beneish M-score for fiscal 2025 is −3.38; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −3.38 | (1.13) |
| FY2024 | −2.25 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.80 | — | 0.74 | |
| Gross margin index | 1.15 | — | 0.61 | |
| Asset quality index | 0.67 | — | 0.27 | |
| Sales growth index | 0.91 | — | 0.81 | |
| Depreciation index | 1.03 | — | 0.12 | |
| SG&A index | 1.18 | — | −0.20 | |
| Total accruals to total assets | (0.13) | — | −0.59 | |
| Leverage index | 0.88 | — | −0.29 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −3.38 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| SIGA Siga Technologies Inc. compare | −4.0× |
| GLAS Glass House Brands Inc. | −3.4× |
| AKBA Akebia Therapeutics, Inc. compare | −3.2× |
| LFCR Lifecore Biomedical, Inc. compare | −3.2× |
| ANIK Anika Therapeutics Inc. compare | −2.8× |
| ADCT ADC Therapeutics SA compare | −2.1× |
| OGI Organigram Global Inc. compare | −1.8× |
| DERM Journey Medical Corporation compare | −0.8× |
| BIOA BioAge Labs, Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI